StockData
Prelude Therapeutics Inc logo

Prelude Therapeutics Inc (PRLD) shareholders

PRLDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 8/3055% above fair value
$3.32−0.09 (-2.64%)

Close on Nov 17, 2026Market cap $264.95MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
62.2%
50M of 80M shares
Institutional holders
75
34 new, 13 sold out
Net institutional buying
19M
In Q2 2026
Insider trades, 12 months
4 buys · 0 sales
Net bought $25.00M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Orbimed Advisors LLC
Joint filing with Orbimed Capital Gp Vi LLC (14.60%)
12,935,07116.00%13D (active) amendmentApr 21, 2026
Felix J. Baker
Joint filing with Baker Bros. Advisors LP (15.50%), Baker Bros. Advisors (GP) LLC (15.50%) and 1 more
10,295,30115.50%13D (active) amendmentApr 20, 2026
Baker Bros. Advisors LP
Joint filing with Baker Bros. Advisors (GP) LLC (23.50%), Julian C. Baker (23.50%) and 1 more
10,269,96823.50%13D (active) amendmentJun 12, 2025
Vaddi Krishna6,745,64713.15%13G (passive) amendmentDec 31, 2025
Rajeev Shah
Joint filing with RA Capital Management, L.P. (9.90%), Peter Kolchinsky (9.90%) and 1 more
6,477,3099.90%13G (passive)Apr 21, 2026
Incyte Corp4,372,1249.90%13G (passive)Nov 3, 2025
Levy Guy
Joint filing with Soleus Capital Management, L.P. (5.20%), Soleus GP, LLC (5.20%)
3,378,3785.20%13G (passive)Apr 21, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of PRLDValueChange% of portfolio
Orbimed Advisors LLC13,724,57117.20%$73.15M+2,815,3151.36%
Baker Bros. Advisors LP10,123,82412.69%$53.96M–0.27%
Ra Capital Management, L.P.6,475,8828.11%$34.52MNew0.30%
Soleus Capital Management, L.P.3,378,3784.23%$18.01MNew0.62%
Kynam Capital Management, LP2,415,0873.03%$12.87M+822,5360.71%
Vanguard Capital Management LLC2,009,4452.52%$10.71M+779,0390.00%
BlackRock, Inc.1,797,5012.25%$9.58M+1,475,6150.00%
Sphera Funds Management Ltd.1,019,8321.28%$5.44M+461,4930.71%
Two Sigma Investments, LP993,3691.24%$5.29M+69,7430.00%
ADAR1 Capital Management, LLC900,9001.13%$4.80M+748,0750.22%
Millennium Management LLC844,9931.06%$4.50M+462,2560.00%
Geode Capital Management, LLC841,8621.05%$4.49M+539,4040.00%
Adage Capital Partners Gp, L.L.C.766,0950.96%$4.08MNew0.01%
Acadian Asset Management LLC611,3590.77%$3.25M+99,8400.00%
Morgan Stanley503,8600.63%$2.69M+181,6990.00%
State Street Corp428,7870.54%$2.29M+290,5560.00%
UBS Group AG318,7970.40%$1.70M+254,2920.00%
Vanguard Fiduciary Trust Co284,8860.36%$1.52M+127,5060.00%
Renaissance Technologies LLC281,2000.35%$1.50M+6,0000.00%
Northern Trust Corp240,5990.30%$1.28M+190,4790.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 20267550M62.2%34 / 258 / 1321M2M
Q1 20265531M38.6%13 / 2012 / 55M1M
Q4 20254828M35.7%10 / 1514 / 93M2M
Q3 20254727M34.0%5 / 823 / 81M1M
Q2 20255027M34.1%8 / 1322 / 171M4M
Q1 20255931M38.3%5 / 1824 / 71M2M
Q4 20246232M40.3%8 / 2612 / 164M8M
Q3 20247036M44.8%17 / 2020 / 75M2M
Q2 20246134M42.5%10 / 1621 / 70M1M
Q1 20245835M43.6%7 / 1721 / 51M1M
Q4 20235635M43.9%6 / 3013 / 105M7M
Q3 20236037M45.9%7 / 2416 / 21M3M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

55 funds held PRLD in Q2 2026, 77% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of PRLDValue% of fundAs of
Vanguard Total Stock Market Index Fund1,513,8251.90%$8.07M0.00%Jun 30, 2026
iShares Russell 2000 ETF657,9870.82%$3.51M0.00%Jun 30, 2026
Vanguard Extended Market Index Fund458,3550.57%$2.44M0.00%Jun 30, 2026
Fidelity Small Cap Index Fund303,5170.38%$1.40M0.00%Jul 31, 2026
iShares Russell 2000 Growth ETF260,7350.33%$1.39M0.01%Jun 30, 2026
SIMT Tax-Managed Small/Mid Cap Fund182,1190.23%$970.69K0.13%Jun 30, 2026
Fidelity Extended Market Index Fund127,8390.16%$501.13K0.00%May 31, 2026
iShares Micro-Cap ETF93,0790.12%$496.11K0.03%Jun 30, 2026
Siit Small Cap Ii Fund82,1000.10%$321.83K0.13%May 31, 2026
Schwab Small-Cap Index Fund67,6220.08%$311.06K0.00%Jul 31, 2026
Ultra-Small Company Market Fund61,0000.08%$325.13K0.22%Jun 30, 2026
Master Small Cap Index Series51,8990.07%$276.62K0.00%Jun 30, 2026
Fidelity Total Market Index Fund43,6160.05%$170.97K0.00%May 31, 2026
Nuveen Small Cap Blend Index Fund37,0230.05%$170.31K0.00%Jul 31, 2026
Fidelity Series Total Market Index Fund36,6010.05%$143.48K0.00%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Krishna VaddiCEO, Director2,693,6233.38%Feb 5, 2026
Charles Q. MorrisChief Medical Officer––May 4, 2026
Sean P. BruskyChief Business Officer100,0000.13%Mar 19, 2026
Peggy ScherleChief Scientific Officer173,5270.22%Feb 5, 2026
Bryant David LimCLO, CFO, Corp Sec.27,4000.03%Feb 5, 2026
Andrew CombsChief Chemistry Officer480,1230.60%Feb 5, 2026
Jane HuangPresident, CMO86,9170.11%Oct 7, 2025
Victor SandorDirector––Jun 10, 2026
Katina DortonDirector––Jun 10, 2026
Paul A. FriedmanDirector347,5220.44%Jun 10, 2026
667, L.P.Director, 10% owner––Jun 10, 2026
Bros. Advisors Lp BakerDirector, 10% owner876,0611.10%Jun 10, 2026
Julian BakerDirector, 10% owner––Jun 10, 2026
Felix BakerDirector, 10% owner––Jun 10, 2026
Brothers Life Sciences LP BakerDirector, 10% owner––Jun 10, 2026
Bros. Advisors (GP) LLC BakerDirector, 10% owner870,8731.09%Jun 10, 2026
David P. BonitaDirector, 10% owner1,126,1261.41%Jun 10, 2026
Martin BablerDirector––Jun 10, 2026
Advisors Llc OrbimedDirector, 10% owner9,250,19111.59%Apr 23, 2026
Capital GP VI LLC OrbiMedDirector, 10% owner––Apr 23, 2026
Capital Llc OrbimedDirector, 10% owner10,119,75612.68%Apr 23, 2026
Genesis GP LLC OrbiMedDirector, 10% owner1,126,1261.41%Apr 23, 2026
Paul C. SchererDirector––Jun 13, 2025
Mardi DierDirector10,0000.01%Jun 13, 2025
Peter Kolchinsky10% owner––Apr 28, 2026
Capital Healthcare Fund LP RA10% owner––Apr 28, 2026
Rajeev M. Shah10% owner6,475,8828.11%Apr 28, 2026
Ra Capital Management, L.P.10% owner7,882,8829.88%Apr 28, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Rajeev M. Shah
10% owner
Apr 27, 2026Other−1,407,000––6,475,882
David P. Bonita
Director, 10% owner
Apr 21, 2026Buy+1,126,126$4.44$5.00M1,126,126
David P. Bonita
Director, 10% owner
Apr 21, 2026Buy+1,689,189$4.44$7.50M11,808,945
Genesis GP LLC OrbiMed
Director, 10% owner
Apr 21, 2026Buy+1,126,126$4.44$5.00M1,126,126
Genesis GP LLC OrbiMed
Director, 10% owner
Apr 21, 2026Buy+1,689,189$4.44$7.50M11,808,945
Jane Huang
President, CMO
Oct 4, 2025Tax withholding−3,355$1.47$4.93K86,917
Jane Huang
President, CMO
Oct 4, 2025Option exercise+9,375––90,272
Jane Huang
President, CMO
Jul 4, 2025Tax withholding−3,355$0.79$2.65K80,897
Jane Huang
President, CMO
Jul 4, 2025Option exercise+9,375––84,252
Jane Huang
President, CMO
Apr 4, 2025Option exercise+9,375––78,232
Jane Huang
President, CMO
Apr 4, 2025Tax withholding−3,355$0.68$2.28K74,877
Andrew Combs
Chief Chemistry Officer
Mar 25, 2025Buy+100,000$0.69$69.00K480,123
Krishna Vaddi
CEO, Director
Mar 25, 2025Buy+675,000$0.69$465.75K1,999,296
Krishna Vaddi
CEO, Director
Mar 21, 2025Buy+15,000$0.73$10.95K1,324,296
Krishna Vaddi
CEO, Director
Mar 20, 2025Buy+5,416$0.73$3.95K1,309,296
Krishna Vaddi
CEO, Director
Mar 17, 2025Buy+9,106$0.75$6.83K1,303,880
Krishna Vaddi
CEO, Director
Mar 14, 2025Buy+29,999$0.75$22.50K1,294,774
Krishna Vaddi
CEO, Director
Mar 13, 2025Buy+50,000$0.72$36.00K1,264,775
Krishna Vaddi
CEO, Director
Mar 12, 2025Buy+47,500$0.71$33.73K1,214,775
Jane Huang
President, CMO
Jan 4, 2025Tax withholding−3,859$1.39$5.36K68,857
Jane Huang
President, CMO
Jan 4, 2025Option exercise+9,375––72,716
Krishna Vaddi
CEO, Director
Dec 31, 2024Buy+5,000$1.21$6.05K142,553
Krishna Vaddi
CEO, Director
Dec 30, 2024Buy+10,000$1.20$12.00K137,553
Andrew Combs
Chief Chemistry Officer
Dec 23, 2024Buy+60,000$1.37$82.20K377,623
Andrew Combs
Chief Chemistry Officer
Dec 20, 2024Buy+3,075$1.15$3.54K317,623
Krishna Vaddi
CEO, Director
Dec 19, 2024Buy+6,888$0.89$6.13K127,553
Bryant David Lim
CLO, Interim CFO, Corp Sec.
Dec 19, 2024Buy+25,000$0.91$22.75K27,400
Krishna Vaddi
CEO, Director
Dec 18, 2024Buy+100,000$0.93$93.00K1,167,275
Jane Huang
President, CMO
Oct 4, 2024Option exercise+9,375––66,690
Jane Huang
President, CMO
Oct 4, 2024Tax withholding−3,349$2.00$6.70K63,341
Jane Huang
President, CMO
Jul 4, 2024Tax withholding−3,347$3.60$12.05K57,315
Jane Huang
President, CMO
Jul 4, 2024Option exercise+9,375––60,662
Jane Huang
President, CMO
Apr 4, 2024Tax withholding−3,347$4.74$15.86K51,287
Jane Huang
President, CMO
Apr 4, 2024Option exercise+9,375––54,634
Jane Huang
President, CMO
Jan 4, 2024Tax withholding−3,844$3.77$14.49K45,259
Jane Huang
President, CMO
Jan 4, 2024Option exercise+9,375––49,103
Jane Huang
President, CMO
Oct 4, 2023Option exercise+9,375––39,728
Jane Huang
President, CMO
Jul 4, 2023Tax withholding−3,242$4.65$15.08K30,353
Jane Huang
President, CMO
Jul 4, 2023Option exercise+9,375––33,595
Krishna Vaddi
CEO, Director
May 25, 2023Buy+900$5.31$4.78K1,067,275
Krishna Vaddi
CEO, Director
May 24, 2023Buy+1,000$5.01$5.01K1,066,375
Bryant David Lim
Chief Legal Officer, Corp Sec.
May 24, 2023Buy+2,400$5.39$12.94K2,400
Laurent Chardonnet
Chief Financial Officer
May 23, 2023Buy+5,000$5.50$27.50K42,165
Krishna Vaddi
CEO, Director
May 23, 2023Buy+11,856$5.63$66.75K1,065,375
Capital Llc Orbimed
Director, 10% owner
May 22, 2023Buy+869,565$5.75$5.00M10,119,756
David P. Bonita
Director, 10% owner
May 22, 2023Buy+869,565$5.75$5.00M10,119,756
Jane Huang
President, CMO
Apr 6, 2023Sale−13,280$6.12$81.27K24,220
Jane Huang
President, CMO
Apr 4, 2023Option exercise+37,500––37,500
Krishna Vaddi
CEO, Director
Dec 20, 2022Buy+19,188$5.13$98.43K120,665
Laurent Chardonnet
Chief Financial Officer
Dec 8, 2022Buy+10,000$4.76$47.60K35,873
Laurent Chardonnet
Chief Financial Officer
Jun 1, 2022Buy+10,000$4.23$42.30K24,500
Andrew Combs
EVP, Head of Chemistry
Mar 31, 2022Option exercise+36,062$1.89$68.16K304,442
Laurent Chardonnet
Chief Financial Officer
Mar 21, 2022Award+6,500$7.51$48.82K14,500
Deborah Morosini
EVP, Chief of Clinical Affairs
Dec 15, 2021Option exercise+3,016$1.89$5.70K3,460
Deborah Morosini
EVP, Chief of Clinical Affairs
Dec 15, 2021Sale(10b5-1 plan)−28,751$13.00$373.76K444
Deborah Morosini
EVP, Chief of Clinical Affairs
Dec 15, 2021Option exercise+25,735$12.85$330.69K29,195
Andrew Combs
EVP, Head of Chemistry
Dec 14, 2021Buy+4,000$11.60$46.40K268,380
Andrew Combs
EVP, Head of Chemistry
Dec 13, 2021Buy+4,000$12.12$48.48K264,380
Krishna Vaddi
President, CEO, Director
Dec 13, 2021Award+8,000$12.13$97.04K1,053,519
Laurent Chardonnet
Chief Financial Officer
Dec 13, 2021Award+5,000$12.28$61.40K8,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
8.80%
4M shares short
Days to cover
9.1
At 0M shares a day
Change since last report
-18.0%
From 5M shares
Short volume, 20 days
52.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Prelude Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,479 shares on Aug 21, 2026 over the last 90 days.

See a number that looks wrong?